{"id":"W2934686121","doi":"10.1016/s2352-3026(19)30026-2","title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":false,"ca_institutions":"Jewish General Hospital; BC Cancer Agency","funders":"Celgene; MorphoSys; Servier; Innovative Research Group Project of the National Natural Science Foundation of China; F. Hoffmann-La Roche; Genentech; AstraZeneca; Gilead Sciences; TG Therapeutics; Pfizer; Takeda Oncology; Amgen","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Rituximab; Refractory (planetary science); Lymphoma; Oncology; Phases of clinical research; Hodgkin lymphoma; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005114908,0.0005550603,0.00276538,0.0002057244,0.0001478305,0.00003932495,0.0004476885,0.000259223,0.0003139501],"category_scores_gemma":[0.0005014762,0.0002833656,0.0001370154,0.0004401121,0.0001663162,0.0001282747,0.0001589978,0.0003708607,0.0003999105],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008860463,"about_ca_system_score_gemma":0.001122536,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001643156,"about_ca_topic_score_gemma":0.001019512,"domain_scores_codex":[0.9961506,0.0005437729,0.0009886759,0.000939948,0.0005561568,0.0008208776],"domain_scores_gemma":[0.9961849,0.001457421,0.0005147507,0.001534515,0.0001342323,0.000174128],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7982686,0.02993865,0.1482656,0.000144487,0.0008523407,0.005608637,0.006961841,0.00001706371,0.00003554684,0.00004973911,0.003057041,0.006800527],"study_design_scores_gemma":[0.7009798,0.008991875,0.2862213,0.0003978125,0.0004348074,0.0001601218,0.0006756543,0.0004257073,0.0001948321,0.00003235045,0.00114579,0.0003399148],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926148,0.0002230759,0.00000701686,0.001147954,0.0003876488,0.004617763,0.0001864002,0.0001074664,0.0007078977],"genre_scores_gemma":[0.9973262,0.0000428467,0.000408879,0.000669702,0.0001529421,0.0003737719,0.0003620755,0.00007091062,0.000592652],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1379557,"threshold_uncertainty_score":0.9999619,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02909414680174879,"score_gpt":0.3019179139198022,"score_spread":0.2728237671180534,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}